1
|
Expression of Cell Cycle Markers and Proliferation Factors during Human Eye Embryogenesis and Tumorigenesis. Int J Mol Sci 2022; 23:ijms23169421. [PMID: 36012688 PMCID: PMC9409163 DOI: 10.3390/ijms23169421] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2022] [Revised: 08/09/2022] [Accepted: 08/17/2022] [Indexed: 11/17/2022] Open
Abstract
The expression pattern of the markers p19, Ki-67, MSX1, MSX2, PDL1, pRB, and CYCLINA2 was quantitatively and semiquantitatively analyzed in histologic sections of the developing and postnatal human eye at week 8, in retinoblastoma, and in various uveal melanomas post hoc studies by double immunofluorescence. The p19 immunoreactivity characterized retinal and/or choroidal cells in healthy and tumor tissues: expression was lower in the postnatal retina than in the developing retina and retinoblastoma, whereas it was high in epithelioid melanomas. Ki67 expression was high in the developing eye, retinoblastoma, and choroidal melanomas. MSX1 and MSX2 expression was similar in the developing eye and retinoblastoma, whereas it was absent in the postnatal eye. Their different expression was evident between epithelioid and myxoid melanomas. Similarly, PDL1 was absent in epithelioid melanomas, whereas it was highly expressed in developing and tumor tissues. Expression of pRB and CYCA2 was characteristic of developing and tumorous eye samples but not of the healthy postnatal eye. The observed expression differences of the analyzed markers correlate with the origin and stage of cell differentiation of the tissue samples. The fine balance of expression could play a role in both human eye development and ocular tumorigenesis. Therefore, understanding their relationship and interplay could open new avenues for potential therapeutic interventions and a better understanding of the mechanisms underlying the developmental plasticity of the eye and the development of neoplasms.
Collapse
|
2
|
Markitantova Y, Simirskii V. Inherited Eye Diseases with Retinal Manifestations through the Eyes of Homeobox Genes. Int J Mol Sci 2020; 21:E1602. [PMID: 32111086 PMCID: PMC7084737 DOI: 10.3390/ijms21051602] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2020] [Revised: 02/21/2020] [Accepted: 02/24/2020] [Indexed: 12/14/2022] Open
Abstract
Retinal development is under the coordinated control of overlapping networks of signaling pathways and transcription factors. The paper was conceived as a review of the data and ideas that have been formed to date on homeobox genes mutations that lead to the disruption of eye organogenesis and result in inherited eye/retinal diseases. Many of these diseases are part of the same clinical spectrum and have high genetic heterogeneity with already identified associated genes. We summarize the known key regulators of eye development, with a focus on the homeobox genes associated with monogenic eye diseases showing retinal manifestations. Recent advances in the field of genetics and high-throughput next-generation sequencing technologies, including single-cell transcriptome analysis have allowed for deepening of knowledge of the genetic basis of inherited retinal diseases (IRDs), as well as improve their diagnostics. We highlight some promising avenues of research involving molecular-genetic and cell-technology approaches that can be effective for IRDs therapy. The most promising neuroprotective strategies are aimed at mobilizing the endogenous cellular reserve of the retina.
Collapse
|
3
|
Babajko S, de La Dure-Molla M, Jedeon K, Berdal A. MSX2 in ameloblast cell fate and activity. Front Physiol 2015; 5:510. [PMID: 25601840 PMCID: PMC4283505 DOI: 10.3389/fphys.2014.00510] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2014] [Accepted: 12/08/2014] [Indexed: 11/29/2022] Open
Abstract
While many effectors have been identified in enamel matrix and cells via genetic studies, physiological networks underlying their expression levels and thus the natural spectrum of enamel thickness and degree of mineralization are now just emerging. Several transcription factors are candidates for enamel gene expression regulation and thus the control of enamel quality. Some of these factors, such as MSX2, are mainly confined to the dental epithelium. MSX2 homeoprotein controls several stages of the ameloblast life cycle. This chapter introduces MSX2 and its target genes in the ameloblast and provides an overview of knowledge regarding its effects in vivo in transgenic mouse models. Currently available in vitro data on the role of MSX2 as a transcription factor and its links to other players in ameloblast gene regulation are considered. MSX2 modulations are relevant to the interplay between developmental, hormonal and environmental pathways and in vivo investigations, notably in the rodent incisor, have provided insight into dental physiology. Indeed, in vivo models are particularly promising for investigating enamel formation and MSX2 function in ameloblast cell fate. MSX2 may be central to the temporal-spatial restriction of enamel protein production by the dental epithelium and thus regulation of enamel quality (thickness and mineralization level) under physiological and pathological conditions. Studies on MSX2 show that amelogenesis is not an isolated process but is part of the more general physiology of coordinated dental-bone complex growth.
Collapse
Affiliation(s)
- Sylvie Babajko
- Laboratory of Molecular Oral Pathophysiology, Centre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale, UMRS 1138 Paris, France ; Laboratory of Molecular Oral Pathophysiology, Centre de Recherche des Cordeliers, Université Paris-Descartes Paris, France ; Laboratory of Molecular Oral Pathophysiology, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie-Paris Paris, France ; Laboratory of Molecular Oral Pathophysiology, Centre de Recherche des Cordeliers, Université Paris-Diderot Paris, France
| | - Muriel de La Dure-Molla
- Laboratory of Molecular Oral Pathophysiology, Centre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale, UMRS 1138 Paris, France ; Laboratory of Molecular Oral Pathophysiology, Centre de Recherche des Cordeliers, Université Paris-Descartes Paris, France ; Laboratory of Molecular Oral Pathophysiology, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie-Paris Paris, France ; Laboratory of Molecular Oral Pathophysiology, Centre de Recherche des Cordeliers, Université Paris-Diderot Paris, France ; Centre de Référence des Maladies Rares de la Face et de la Cavité Buccale MAFACE, Hôpital Rothschild Paris, France
| | - Katia Jedeon
- Laboratory of Molecular Oral Pathophysiology, Centre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale, UMRS 1138 Paris, France ; Laboratory of Molecular Oral Pathophysiology, Centre de Recherche des Cordeliers, Université Paris-Descartes Paris, France ; Laboratory of Molecular Oral Pathophysiology, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie-Paris Paris, France ; Laboratory of Molecular Oral Pathophysiology, Centre de Recherche des Cordeliers, Université Paris-Diderot Paris, France
| | - Ariane Berdal
- Laboratory of Molecular Oral Pathophysiology, Centre de Recherche des Cordeliers, Institut National de la Santé et de la Recherche Médicale, UMRS 1138 Paris, France ; Laboratory of Molecular Oral Pathophysiology, Centre de Recherche des Cordeliers, Université Paris-Descartes Paris, France ; Laboratory of Molecular Oral Pathophysiology, Centre de Recherche des Cordeliers, Université Pierre et Marie Curie-Paris Paris, France ; Laboratory of Molecular Oral Pathophysiology, Centre de Recherche des Cordeliers, Université Paris-Diderot Paris, France ; Centre de Référence des Maladies Rares de la Face et de la Cavité Buccale MAFACE, Hôpital Rothschild Paris, France
| |
Collapse
|
4
|
Plaisancié J, Collet C, Pelletier V, Perdomo Y, Studer F, Fradin M, Schaefer E, Speeg-Schatz C, Bloch-Zupan A, Flori E, Dollfus H. MSX2 Gene Duplication in a Patient with Eye Development Defects. Ophthalmic Genet 2014; 36:353-8. [PMID: 24666290 DOI: 10.3109/13816810.2014.886270] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
BACKGROUND MSX2 mutations are a very rare cause of craniosynostosis. Gain-of-function mutations may lead to the Boston-type craniosynostosis with limb defects and refraction errors, whereas loss-of-function mutations causes primary osseous defects such as enlarged parietal foramina. MATERIALS AND METHODS Herein we report the case of a child with bicoronal synostosis and cutaneous syndactylies, who presented iridal and chorioretinal colobomas. Due to the craniofacial features that were prominent in the clinical picture, the genes involved in craniosynostosis were explored. RESULTS The patient disclosed an intragenic duplication of the entire MSX2 gene whereas no mutation was identified in any major genes known to be involved in craniosynostosis. CONCLUSION This is the first report of an eye development defect due to an increase in the MSX2 copy number in a human being. The implication of this gene in eye development has already been shown in several animal models. Indeed, overexpression of the Msx2 gene in a mouse model resulted also in optic nerve aplasia and microphthalmia. This report expands the phenotypic spectrum of the MSX2 mutations impacting early ocular development knowledge.
Collapse
Affiliation(s)
- Julie Plaisancié
- a Centre de référence pour les Affections Rares en Génétique Ophtalmologique (CARGO), Hôpital Civil , Strasbourg , France
| | - Corinne Collet
- b Service de Biochimie et Biologie Moléculaire, Hôpital Lariboisière , Paris , France
| | - Valerie Pelletier
- a Centre de référence pour les Affections Rares en Génétique Ophtalmologique (CARGO), Hôpital Civil , Strasbourg , France
| | - Yaumara Perdomo
- a Centre de référence pour les Affections Rares en Génétique Ophtalmologique (CARGO), Hôpital Civil , Strasbourg , France
| | - Fouzia Studer
- a Centre de référence pour les Affections Rares en Génétique Ophtalmologique (CARGO), Hôpital Civil , Strasbourg , France
| | - Mélanie Fradin
- c Service de Génétique Médicale, Hôpital de Hautepierre , Strasbourg , France
| | - Elise Schaefer
- c Service de Génétique Médicale, Hôpital de Hautepierre , Strasbourg , France
| | | | - Agnès Bloch-Zupan
- e Reference Centre for Orodental Manifestations of Rare Diseases, Pôle de Médecine et Chirurgie Bucco-Dentaires, Hôpitaux Universitaires de Strasbourg , Strasbourg , France
| | - Elisabeth Flori
- f Laboratoire de Cytogénétique , Hôpital de Hautepierre , Strasbourg , France , and
| | - Hélène Dollfus
- a Centre de référence pour les Affections Rares en Génétique Ophtalmologique (CARGO), Hôpital Civil , Strasbourg , France .,c Service de Génétique Médicale, Hôpital de Hautepierre , Strasbourg , France .,g Laboratoire de Génétique Médicale , INSERM U1112 , Strasbourg , France
| |
Collapse
|
5
|
Nagel S, Ehrentraut S, Meyer C, Kaufmann M, Drexler HG, MacLeod RAF. Oncogenic deregulation of NKL homeobox gene MSX1 in mantle cell lymphoma. Leuk Lymphoma 2014; 55:1893-903. [PMID: 24237447 DOI: 10.3109/10428194.2013.864762] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
NKL homeobox gene MSX1 is physiologically expressed during embryonic hematopoiesis. Here, we detected MSX1 overexpression in three examples of mantle cell lymphoma (MCL) and one of acute myeloid leukemia (AML) by screening 96 leukemia/lymphoma cell lines via microarray profiling. Moreover, in silico analysis identified significant overexpression of MSX1 in 3% each of patients with MCL and AML, confirming aberrant activity in subsets of both types of malignancies. Comparative expression profiling analysis and subsequent functional studies demonstrated overexpression of histone acetyltransferase PHF16 together with transcription factors FOXC1 and HLXB9 as activators of MSX1 transcription. Additionally, we identified regulation of cyclin D1/CCND1 by MSX1 and its repressive cofactor histone H1C. Fluorescence in situ hybridization in MCL cells showed that t(11;14)(q13;q32) results in detachment of CCND1 from its corresponding repressive MSX1 binding site. Taken together, we uncovered regulators and targets of homeobox gene MSX1 in leukemia/lymphoma cells, supporting the view of a recurrent genetic network that is reactivated in malignant transformation.
Collapse
Affiliation(s)
- Stefan Nagel
- Department of Human and Animal Cell Lines, Leibniz-Institute DSMZ - German Collection of Microorganisms and Cell Cultures , Braunschweig , Germany
| | | | | | | | | | | |
Collapse
|